Mr. Tony  Wood

Chief Scientific Officer

Mr. Philip C. Thomson

Pres of Global Affairs

Ms. Emma Natasha Walmsley

Chief Executive Officer & Director

Ms. Diana  Conrad

Chief People Officer

Ms. Sally  Jackson

Senior Vice President of Global Communications & Chief Executive Officer Office

Mr. James  Ford

Senior Vice President & Group Gen. Counsel of Legal & Compliance

Mr. David Simon Redfern

Chief Strategy Officer

Ms. Shobie  Ramakrishnan

Chief Digital & Technology Officer

Ms. Sarah  Elton-Farr

Head of Investor Relations

Mr. Iain James Mackay

Chief Financial Officer & Executive Director

Ms. Julie  Brown

Chief Financial Officer

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

In the current economic climate of rising interest rates, persistent inflation, simmering geopolitical risks and looming recessionary threats, it's crucial to prioritize quality, safety and high dividends when selecting stocks. This article explores three high dividend stocks with appealing total return potential.

3 High Dividend Stocks With Attractive Total Return Potential

GSK's RSV vaccine candidate could prevent deaths and hospitalizations in older patients. The product could end up generating over $1 billion in annual revenue for the company.

Could This Be the Next Blockbuster Vaccine for This Big Pharma Stock?

2023 is flying by as two months are already in the books and that fact simply highlights to me the importance of staying invested in the stock market during the good times and bad. VZ stock is trading with a low forward PE of just over 8 and sports a very juicy yield getting close to 7% and a moderate payout ratio of around 51% making this dividend appear to be very safe going forward.

March 2023 Stock Considerations

GSK PLC (LSE:GSK, NYSE:GSK)'s respiratory syncytial virus (RSV) vaccine has been endorsed by advisors to the US Food & Drug Administration, who assessed its safety and efficacy in older adults. The decision puts GSK in direct competition with Pfizer Inc (NYSE:PFE), which has also developed a promising RSV vaccine.

GSK neck and neck with Pfizer in the race to get first RSV jab to market

CNBC's Meg Tirrell joins 'Power Lunch' to discuss GSK PLC's RSV vaccine receiving FDA support, ongoing questions around the drug's approval and the timeline for the drug to be available for children.

FDA advisory panel votes in favor of adult RSV vaccine from GSK PLC

GSK Raises Guidance as Earnings Help Shore Up Position of CEO 

Drugmakers Fight Over Lucrative Pneumonia Vaccines

GSK Raises Full-Year Forecast 

Pfizer Steps Ahead of Glaxo in Race for Maternal RSV Vaccine

Sanofi and Glaxo Report Dual Disappointments. The Stocks Are Holding Up.

Unilever Walks Away From Glaxo Consumer-Healthcare Deal 

GlaxoSmithKline Rejects Unilever Offer for its Consumer Health Unit

Unilever Makes Approach for Glaxo’s Consumer-Healthcare Business

Vir and Glaxo's Drug Could Be Last Antibody Treatment Standing Against Omicron

Tesla, Intel, Bitcoin: What to Watch in the Stock Market Today

Vir Biotechnology, Digital World Acquisition, Apple: What to Watch in the Stock Market Today

Powered by AI

GSK plc

34.24